Ubs Asset Management Americas Inc Seagen Inc. Transaction History

Ubs Asset Management Americas Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $3.72 Million - $4.19 Million	-19,401 Reduced 2.55%	741,608 $157 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $3.1 Million - $4.94 Million	24,321 Added 3.3%	761,009 $154 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $556,920 - $660,361	-4,745 Reduced 0.64%	736,688 $94.7 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $2.24 Million - $2.98 Million	16,558 Added 2.28%	741,433 $101 Million
Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $8.58 Million - $14.1 Million	-78,866 Reduced 9.81%	724,875 $128 Million

Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $90.8 Million - $120 Million	-759,174 Reduced 48.57%	803,741 $116 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $40.2 Million - $53.8 Million	281,872 Added 22.0%	1,562,915 $242 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $5.06 Million - $6.04 Million	35,553 Added 2.85%	1,281,043 $218 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $37.7 Million - $45 Million	279,376 Added 28.92%	1,245,490 $197 Million
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $133 Million - $184 Million	966,114 New	966,114 $134 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.